Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Seattle Genetics & Astellas Enter An Agreement With Merck To Assess Effectiveness Of Drug For Metastatic Urothelial Cancer

By John F. Heerdink, Jr.

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program

Merck has entered into a collective agreement through a subsidiary of Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc to evaluate the efficacy and combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate enfortumab vedotin and Merck’s anti-PD-1 therapy, KEYTRUDA® in patients with untreated metastatic urothelial cancer previously.

We look forward to initiating a randomized phase 3 trial in patients with previously untreated locally advanced or metastatic urothelial cancer. Recent data from a phase 1b trial of enfortumab vedotin in combination with pembrolizumab showed evidence of clinical activity leading to the development of this phase 3 trial” stated Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.

Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas stated, “An unmet medical need exists for previously untreated patients with metastatic urothelial cancer, and we are committed to studying enfortumab vedotin in combination with other agents in different stages of urothelial cancer. We look forward to further evaluating enfortumab vedotin and pembrolizumab in this high unmet need patient population.”

Urothelial cancer is the most common type of bladder cancer. Last Year globally, approximately 549k people were diagnosed with bladder cancer reporting 200k deaths worldwide.

To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.


Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website:www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!






nov3(8)

Post View Count : 1023
(Read Original Story: Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer in Business Wire)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us